Dynavax Technologies to be Acquired by Sanofi for $221.50 per Share
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2h ago
0mins
Source: Businesswire
- Acquisition Investigation: Former Louisiana Attorney General Charles C. Foti and his law firm are investigating the proposed acquisition of Dynavax by Sanofi, aiming to assess whether the cash offer of $221.50 per share is adequate, which could impact shareholder rights.
- Shareholder Rights Concern: KSF is determining if the transaction undervalues Dynavax, potentially leading to shareholder dissatisfaction with the acquisition terms, which may affect future shareholder confidence in the company.
- Transaction Structure Analysis: The deal is structured as a tender offer, indicating high time sensitivity, requiring shareholders to act quickly to protect their interests, which could influence the smooth execution of the transaction.
- Legal Consultation Opportunity: KSF offers no-obligation legal consultation services, encouraging shareholders to discuss the fairness of the deal, which may trigger further legal challenges from shareholders regarding the transaction.
DVAX
$15.37+Infinity%1D
Analyst Views on DVAX
Wall Street analysts forecast DVAX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DVAX is 21.00 USD with a low forecast of 11.00 USD and a high forecast of 32.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
4 Buy
0 Hold
1 Sell
Moderate Buy
Current: 15.380
Low
11.00
Averages
21.00
High
32.00
Current: 15.380
Low
11.00
Averages
21.00
High
32.00
About DVAX
Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company developing and commercializing vaccines to help protect against infectious diseases. The Company has two commercial products: HEPLISAV-B vaccine (Hepatitis B Vaccine (Recombinant), Adjuvanted), and CpG 1018 adjuvant. The HEPLISAV-B vaccine is used for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose in-one-month adult hepatitis B vaccine. CpG 1018 adjuvant is used in HEPLISAV-B and multiple adjuvanted COVID-19 vaccines. The Company is advancing a pipeline of differentiated product candidates that leverage its CpG 1018 adjuvant to develop improved vaccines in indications with unmet medical needs. Its pipeline programs include Shingles vaccine program (Z-1018) and Plague vaccine program. Z-1018 is an investigational vaccine candidate being developed for the prevention of shingles in adults aged 50 and older.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
